Citadel Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $562K | Buy |
2,800
+1,800
| +180% | +$372K | ﹤0.01% | 9019 |
|
|
2025
Q4 | $207K | Sell |
1,000
-500
| -33% | -$99.9K | ﹤0.01% | 10977 |
|
|
2025
Q3 | $269K | Sell |
1,500
-1,100
| -42% | -$187K | ﹤0.01% | 10610 |
|
|
2025
Q2 | $419K | Buy |
2,600
+200
| +8% | +$31.9K | ﹤0.01% | 9042 |
|
|
2025
Q1 | $408K | Sell |
2,400
-500
| -17% | -$86.8K | ﹤0.01% | 8932 |
|
|
2024
Q4 | $482K | Buy |
2,900
+200
| +7% | +$34.2K | ﹤0.01% | 8640 |
|
|
2024
Q3 | $464K | Sell |
2,700
-1,000
| -27% | -$166K | ﹤0.01% | 8422 |
|
|
2024
Q2 | $570K | Buy |
3,700
+2,900
| +363% | +$435K | ﹤0.01% | 7796 |
|
|
2024
Q1 | $123K | Buy |
800
+400
| +100% | +$61K | ﹤0.01% | 11077 |
|
|
2023
Q4 | $63.2K | Sell |
400
-1,900
| -83% | -$273K | ﹤0.01% | 11525 |
|
|
2023
Q3 | $337K | Buy |
2,300
+700
| +44% | +$107K | ﹤0.01% | 8928 |
|
|
2023
Q2 | $245K | Sell |
1,600
-4,900
| -75% | -$764K | ﹤0.01% | 9447 |
|
|
2023
Q1 | $1.01M | Buy |
6,500
+3,500
| +117% | +$550K | ﹤0.01% | 6769 |
|
|
2022
Q4 | $462K | Sell |
3,000
-5,300
| -64% | -$782K | ﹤0.01% | 8410 |
|
|
2022
Q3 | $1.09M | Buy |
+8,300
| New | +$1.16M | ﹤0.01% | 6799 |
|
|
2021
Q4 | – | Sell |
-2,500
| Closed | -$415K | – | 14057 |
|
|
2021
Q3 | $415K | Sell |
2,500
-2,500
| -50% | -$427K | ﹤0.01% | 10328 |
|
|
2021
Q2 | $863K | Buy |
5,000
+2,000
| +67% | +$330K | ﹤0.01% | 8736 |
|
|
2021
Q1 | $482K | Buy |
3,000
+900
| +43% | +$154K | ﹤0.01% | 9752 |
|
|
2020
Q4 | $353K | Sell |
2,100
-1,400
| -40% | -$227K | ﹤0.01% | 8778 |
|
|
2020
Q3 | $550K | Sell |
3,500
-2,300
| -40% | -$376K | ﹤0.01% | 7120 |
|
|
2020
Q2 | $973K | Sell |
5,800
-900
| -13% | -$141K | ﹤0.01% | 5883 |
|
|
2020
Q1 | $879K | Buy |
6,700
+2,400
| +56% | +$342K | ﹤0.01% | 5560 |
|
|
2019
Q4 | $639K | Sell |
4,300
-100
| -2% | -$13.7K | ﹤0.01% | 6412 |
|
|
2019
Q3 | $545K | Buy |
4,400
+600
| +16% | +$79.9K | ﹤0.01% | 6591 |
|
|
2019
Q2 | $535K | Sell |
3,800
-2,900
| -43% | -$400K | ﹤0.01% | 6727 |
|
|
2019
Q1 | $1.01M | Sell |
6,700
-1,900
| -22% | -$273K | ﹤0.01% | 5563 |
|
|
2018
Q4 | $1.07M | Buy |
8,600
+400
| +5% | +$54.7K | ﹤0.01% | 5200 |
|
|
2018
Q3 | $1.3M | Sell |
8,200
-3,800
| -32% | -$575K | ﹤0.01% | 5095 |
|
|
2018
Q2 | $1.68M | Buy |
12,000
+7,500
| +167% | +$1.03M | ﹤0.01% | 4372 |
|
|
2018
Q1 | $598K | Sell |
4,500
-2,400
| -35% | -$328K | ﹤0.01% | 5596 |
|
|
2017
Q4 | $860K | Buy |
6,900
+1,400
| +25% | +$173K | ﹤0.01% | 4873 |
|
|
2017
Q3 | $682K | Buy |
5,500
+200
| +4% | +$23.7K | ﹤0.01% | 4880 |
|
|
2017
Q2 | $604K | Buy |
5,300
+1,400
| +36% | +$151K | ﹤0.01% | 4856 |
|
|
2017
Q1 | $411K | Sell |
3,900
-4,400
| -53% | -$441K | ﹤0.01% | 5354 |
|
|
2016
Q4 | $754K | Sell |
8,300
-7,000
| -46% | -$656K | ﹤0.01% | 4263 |
|
|
2016
Q3 | $1.53M | Buy |
+15,300
| New | +$1.5M | ﹤0.01% | 3290 |
|
Other funds holding FBT
BFG
Citadel Advisors's FBT Position: Q4 2025 in Review
Citadel Advisors sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q4 2025, closing a stake of 26,102 shares — an estimated $5.22M sold.
Citadel Advisors first reported a position in FBT in Q4 2014 and held it in 40 quarters. The position peaked at $9.4M in Q3 2015. 279 funds tracked by Wall St. Rank hold FBT as of Q4 2025.
- Citadel Advisors reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 26,102 First Trust NYSE Arca Biotechnology Index Fund shares in Q4 2025, an estimated $5.22M.
- Citadel Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2014 and held it in 40 quarters.
- Citadel Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $9.4M in Q3 2015.
- 279 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.